[
  {
    "ts": null,
    "headline": "Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference",
    "summary": "IRVINE, Calif., December 04, 2025--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunit",
    "url": "https://finnhub.io/api/news?id=00f714f398186afe18f2ef4e14c34625760f4639252ca0d9e0d50495c340fca0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764856800,
      "headline": "Edwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference",
      "id": 137680314,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "IRVINE, Calif., December 04, 2025--Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated growth, Edwards is uniquely positioned with leading therapies across its core structural heart innovations for patients with aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR) and pulmonic diseases, and expanding into emerging opportunit",
      "url": "https://finnhub.io/api/news?id=00f714f398186afe18f2ef4e14c34625760f4639252ca0d9e0d50495c340fca0"
    }
  }
]